Ablynx NV (ABLX.BR) Key Developments | Reuters.com
Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.34EUR
27 Jun 2016
Change (% chg)

€0.16 (+1.39%)
Prev Close
€11.19
Open
€11.49
Day's High
€11.50
Day's Low
€11.19
Volume
46,873
Avg. Vol
160,798
52-wk High
€16.20
52-wk Low
€10.00

Latest Key Developments (Source: Significant Developments)

Van Herk Investments announce 3.02 pct shareholding in Ablynx
Thursday, 16 Jun 2016 01:00am EDT 

Ablynx NV :Van Herk Investments announce 3.02 pct shareholding in Ablynx.  Full Article

Ablynx successfully raises 74.2 mln euros
Thursday, 2 Jun 2016 03:17am EDT 

Ablynx NV : Announced on Wednesday that it has raised 74.2 million euros ($83.1 million) through a private placement of new shares via an accelerated book building procedure announced on June 1, 2016 .Has placed 5,533,720 new shares with domestic and international institutional investors at a price of 13.40 euros per share, i.e. a 6.29 pct discount to June 1 closing price.  Full Article

Ablynx to raise capital through private placement of new shares
Wednesday, 1 Jun 2016 11:42am EDT 

Ablynx Nv : To raise capital through a private placement of new shares . To raise gross proceeds of up to approximately 60 million euro ($67.0 million) .J.P. MORGAN Securities Plc, Jefferies International Limited and KBC Securities are acting as joint bookrunners.  Full Article

Ablynx Q1 cash position up at 233.7 million euros
Thursday, 12 May 2016 01:01am EDT 

Ablynx NV : Q1 revenues up 94 pct to 27.4 million euros ($31.3 million)(Q1 2015: 14.1 million euros) . Q1 233.7 million euros in cash, cash equivalents, restricted cash and short-term investments (Q1 2015: 193.3 million euros) . Q1 operating result of negative 0.7 million euros (Q1 2015: loss of 5.0 million euros) . Financial guidance and 2016 outlook confirmed . Company reiterates its net cash burn guidance for the full year 2016 of 65-75 million euros . In Q4 Ablynx expects to start a phase II efficacy study with the wholly-owned inhaled anti-rsv nanobody, ALX-0171 .In Q3, expects that the first patients from the phase III HERCULES study of its wholly-owned anti-vwf nanobody, caplacizumab, will have rolled-over into a 3 year follow-up study.  Full Article

Ablynx meets primary endpoint in anti-RSV nanobody phase I/IIa study
Tuesday, 3 May 2016 01:00am EDT 

Ablynx NV:Reports positive top line results for its inhaled anti-RSV nanobody (ALX-0171) in a phase I/IIa study in infants hospitalized with an RSV infection.Primary endpoint of safety and tolerability met.Anti-viral effect demonstrated and encouraging initial indication of therapeutic effect.Results support advancing programme into a phase II efficacy study in infants.Potential general proof-of-principle for administration of nanobodies by inhalation.  Full Article

Ablynx to receive EUR 8 mln milestone as Boehringer Ingelheim starts Phase I study
Thursday, 21 Apr 2016 01:00am EDT 

Ablynx NV:Ablynx to receive an 8 million euros milestone as Boehringer Ingelheim starts a Phase I study with an anti-CX3CR1 nanobody.  Full Article

Ablynx announces warrant exercise
Tuesday, 23 Feb 2016 01:00am EST 

Ablynx NV:Announces warrant exercise.‍Announced that an additional 7,521 common shares have been issued by company in exchange for 34,726.41 euros ($38,324.07) as result of exercise of warrants.‍As a result of this transaction, Ablynx now has 55,108,065 shares outstanding.  Full Article

Ablynx completes enrolment of phase I/IIa safety study with anti-RSV nanobody
Thursday, 17 Dec 2015 01:14am EST 

Ablynx NV:Ablynx completes enrolment of the first-in-infant phase I/IIa safety study with its anti-RSV nanobody and extends the trial for younger infants.Target enrolment of 35 infants, aged 3-24 months, completed.‍On track to publish top line results in first half of 2016​.‍Age requirement for infants in trial has been reduced from 3 months to 1 month.Results from this extension will be available in the second half of 2016.  Full Article

Ablynx says JP Morgan Asset Management Holdings exceeds 3 pct threshold
Wednesday, 2 Dec 2015 01:00am EST 

Ablynx NV:JP Morgan Asset Management Holdings announce 3.33 pct shareholding in Ablynx.JP Morgan Asset Management Holdings notified that they have exceeded the 3 pct threshold and now hold 1,813,725 Ablynx shares.  Full Article

Ablynx announces nanobody drug discovery collaboration with Novo Nordisk
Wednesday, 25 Nov 2015 01:00am EST 

Ablynx NV:Announces nanobody drug discovery collaboration with Novo Nordisk A/S.Ablynx to receive a 5 million euro upfront payment, research funding, potential future milestones and royalties on net sale.If Novo Nordisk decides to exercise option to second programme, company will pay ablynx an exercise fee of 4 million euros.Collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody drug candidates.In addition, Ablynx is eligible to receive potential development, regulatory and commercial milestone payments of up to 182 million euros per programme.Novo Nordisk will be responsible for the development, manufacturing and commercialisation of any products resulting from this agreement.  Full Article

BRIEF-Van Herk Investments announce 3.02 pct shareholding in Ablynx

* Van Herk Investments announce 3.02 pct shareholding in Ablynx Source text for Eikon: Further company coverage: (Gdynia Newsroom:)